Wockhardt has received a ‘warning letter’ from USFDA for its Waluj facility, which lists the observations made during the inspection. The company has already initiated several corrective actions to resolve the same. The company continues to cooperate with USFDA to resolve the issues at the earliest. The company had earlier received an 'import alert' from USFDA on one of its manufacturing unit located in Waluj near Aurangabad on May 24, 2013.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
